CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers.

摘要

hi this issue or Cancer Biology & Therapy, Appaiah and colleagues put forth a thorough study that combines cell culture modeling, in vivo work and computational microarray analysis of breast cancers to evaluate a powerful and complex CXCR4 signaling pathway in breast cancer cells.1 The CXCR4 receptor and its ligand, CXCL12 (SDF-1), were first identified in the context of the trafficking and homeostasis of immune cells/ Subsequently, it has been determined that both CXCL12 and CXCR4 regulates several key processes in a wide variety of cancers (reviewed in ref. 3). Functions ol CXCL12 and CXCR4 were first described in metastatic breast cancer, and this signaling pathway has also been implicated in primary breast tumor biology and prognosis.